

# National Notifiable Infectious Diseases and Conditions: United States

TABLE 1. Reported cases of notifiable diseases and rates per 100,000, excluding U.S. territories -- United States, 2016  
(Accessible Version: <https://wonder.cdc.gov/nndss/static/2016/annual/2016-table1.html>)

Disease	Case Count	Rate
Anthrax	—	—
Arboviral diseases		
Chikungunya virus disease	247	0.08
Eastern equine encephalitis virus disease		
Neuroinvasive	7	0.00
Non-neuroinvasive	—	—
Jamestown Canyon virus disease		
Neuroinvasive	7	0.00
Non-neuroinvasive	8	0.00
La Crosse virus disease		
Neuroinvasive	31	0.01
Non-neuroinvasive	4	0.00
Powassan virus disease		
Neuroinvasive	21	0.01
Non-neuroinvasive	1	0.00
St. Louis encephalitis virus disease		
Neuroinvasive	7	0.00
Non-neuroinvasive	1	0.00
West Nile virus disease		
Neuroinvasive	1,308	0.40
Non-neuroinvasive	841	0.26
Western equine encephalitis virus disease		
Neuroinvasive	—	—
Non-neuroinvasive	—	—
Babesiosis		
Total	1,910	0.83
Confirmed	1,585	0.69
Probable	325	0.14
Botulism		
Total	201	0.06
Foodborne	31	0.01
Infant *	144	3.63
Other (wound & unspecified)	26	0.01
Brucellosis	127	0.04
Campylobacteriosis	60,120	18.61
Chancroid	7	0.00
<i>Chlamydia trachomatis</i> infection	1,598,354	494.65
Cholera	15	0.00
Coccidioidomycosis †	11,829	9.01
Cryptosporidiosis		
Total	13,453	4.16
Confirmed	8,637	2.67
Probable	4,816	1.49
Cyclosporiasis	537	0.18
Dengue virus infections §		
Dengue	903	0.28
Dengue-like illness	40	0.01
Severe dengue	10	0.00
Diphtheria	—	—
Ehrlichiosis and Anaplasmosis		
<i>Anaplasma phagocytophilum</i> infection	4,151	1.33
<i>Ehrlichia chaffeensis</i> infection	1,377	0.44
<i>Ehrlichia ewingii</i> infection	22	0.01
Undetermined ehrlichiosis/anaplasmosis	200	0.06

TABLE 1. Reported cases of notifiable diseases and rates per 100,000, excluding U.S. territories - - United States, 2016  
(Accessible Version: <https://wonder.cdc.gov/nndss/static/2016/annual/2016-table1.html>)

Disease	Case Count	Rate
Giardiasis	16,310	6.43
Gonorrhea	468,514	144.99
<i>Haemophilus influenzae</i> , invasive disease		
All ages, all serotypes	4,895	1.51
Age <5 years ¶		
Serotype b	30	0.15
Non-b serotype	159	0.80
Nontypeable	196	0.98
Unknown serotype	187	0.94
Hansen's disease	78	0.03
Hantavirus infection, non-hantavirus pulmonary syndrome	6	0.00
Hantavirus pulmonary syndrome	31	0.01
Hemolytic uremic syndrome post-diarrheal	307	0.10
Hepatitis **		
A, acute	2,007	0.62
B, acute	3,218	1.00
B, perinatal infection ††	32	0.40
C, acute	2,942	0.97
Human immunodeficiency virus diagnoses	34,775	10.76
Influenza-associated pediatric mortality §§	82	0.11
Invasive pneumococcal disease		
All ages	17,626	7.32
Confirmed	17,603	7.31
Probable	23	0.01
Age <5 years ¶	1,142	0.44
Confirmed	1,137	7.13
Probable	5	0.03
Legionellosis	6,141	1.90
Leptospirosis	78	0.03
Listeriosis	786	0.24
Lyme disease		
Total	36,429	11.32
Confirmed	26,203	8.15
Probable	10,226	3.18
Malaria	1,955	0.61
Measles		
Total	85	0.03
Indigenous	68	0.02
Imported	17	0.01
Meningococcal disease		
All serogroups	375	0.12
Serogroups ACWY	126	0.04
Serogroup B	86	0.03
Other serogroups	21	0.01
Unknown serogroup	142	0.04
Mumps	6,369	1.97
Novel Influenza A virus infections	23	0.01
Pertussis	17,972	5.56
Plague	4	0.00
Poliomyelitis, paralytic	—	—
Poliovirus infection, nonparalytic	—	—
Psittacosis	12	0.00
Q fever		
Total	164	0.05
Acute	132	0.04
Chronic	32	0.01
Rabies		
Animal	4,609	1.51

TABLE 1. Reported cases of notifiable diseases and rates per 100,000, excluding U.S. territories - - United States, 2016  
(Accessible Version: <https://wonder.cdc.gov/nndss/static/2016/annual/2016-table1.html>)

Disease	Case Count	Rate
Human	—	—
Rubella	1	0.00
Rubella, congenital syndrome *	2	0.05
Salmonellosis	53,850	16.67
Severe acute respiratory syndrome-associated coronavirus disease	—	—
Shiga toxin-producing <i>Escherichia coli</i> ¶¶¶	8,169	2.53
Shigellosis	21,097	6.53
Smallpox	—	—
Spotted fever rickettsiosis		
Total	4,269	1.33
Confirmed	154	0.05
Probable	4,115	1.28
Streptococcal toxic shock syndrome	283	0.14
Syphilis		
Total, all stages ***	88,042	27.25
Congenital *	628	15.82
Primary and secondary	27,814	8.61
Tetanus	34	0.01
Toxic shock syndrome (other than Streptococcal)	40	0.02
Trichinellosis	26	0.01
Tuberculosis	9,272	2.87
Tularemia	230	0.07
Typhoid fever	376	0.12
Vancomycin-intermediate <i>Staphylococcus aureus</i>	108	0.04
Vancomycin-resistant <i>Staphylococcus aureus</i>	—	—
Varicella morbidity	8,953	3.45
Varicella mortality	3	0.00
Vibriosis		
Total	1,273	0.40
Confirmed	1,241	0.39
Probable	32	0.01
Viral hemorrhagic fevers		
Crimean-Congo hemorrhagic fever virus	—	—
Ebola virus	—	—
Guanarito virus	—	—
Junin virus	—	—
Lassa virus	—	—
Lujo virus	—	—
Machupo virus	—	—
Marburg virus	—	—
Sabia virus	—	—
Yellow fever	1	0.00
Zika virus		
Zika virus disease, congenital *,†††	30	0.76
Zika virus disease, non-congenital	5,132	1.59
Zika virus infection, congenital *,†††	45	1.13
Zika virus infection, non-congenital	911	0.28

—: No reported cases

\* The rate is calculated using population less than 1 year of age.

† Reportable in <25 states.

§ Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).

¶¶ The rate is calculated using population less than 5 years of age.

\*\* Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at <https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm>.

†† The rate is calculated using population less than 2 years of age.

§§ The rate is calculated using population less than 18 years of age.

¶¶¶ Includes *Escherichia coli* O157:H7; shiga toxin-positive, serogroup non-O157; and shiga toxin positive, not serogrouped.

\*\*\* Includes syphilis of all stages, including cases where stage of syphilis is not stated.

††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at <https://www.cdc.gov/zika/reporting/pregnancy-outcomes.html>. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.

---

#### Notes:

- These are **annual** cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
- The list of national notifiable infectious diseases and conditions for 2016 and their national surveillance case definitions are available at <https://www.cdc.gov/nndss/conditions/notifiable/2016/infectious-diseases/>. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2015 by CSTE for national surveillance, that were implemented in January 2016, including updated surveillance case definitions for acute hepatitis C and chronic hepatitis C virus infections. 2016 data are reported through June 30, 2017. Publication criteria for the finalized 2016 data are available at [/nndss/documents/2016\\_NNDSS\\_Publication\\_Criteria.pdf](/nndss/documents/2016_NNDSS_Publication_Criteria.pdf). See also [Guide to Interpreting Provisional and Finalized NNDSS Data](#).
- Population estimates for incidence rates are July 1st, 2016 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for July 1, 2011 - July 1, 2016, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2016), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states as of June 26, 2017 are available at [https://www.cdc.gov/nchs/nvss/bridged\\_race/data\\_documentation.htm](https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm). Population estimates for territories are the 2016 mid-year estimates from the U.S. Census Bureau International Data Base accessed on July 24, 2017 at <https://www.census.gov/population/international/data/idb/informationGateway.php>. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
- Annual tables for 2016 and later years are available on [CDC WONDER](#).
- Annual summary reports from 1993-2015 are available as published in the *MMWR*.
- Annual summary reports from 1952-1992 are available as published in the *MMWR* in the [CDC Stacks](#).

#### Suggested Citation:

- Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2016 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Division of Health Informatics and Surveillance, 2017. Available at: <https://www.cdc.gov/nndss/infectious-tables.html>.

### National Notifiable Diseases Surveillance System

Provided by [CDC WONDER](#)